March 31, 2026 Rare/Orphan and Pediatric Disease Programs: Quarterly Newsletter March 2026 Welcome to the Rare/Orphan and Pediatric Disease Programs quarterly newsletter. In between major announcements...
March 31, 2026 C-Path Newsletter Q1 2026: Momentum in Motion As we close the first quarter of the year, we are energized by the opportunities ahead to further strengthen collaboration...
June 9, 2025 Delivering regulatory impact from consortium-based projects Multiple consortia have been established in the past two decades with the aim of tackling roadblocks in the development of...
C-Path and CHDI launch consortium to accelerate development of Huntington’s disease therapies Tucson, AZ, and New York, NY – March 28, 2018 – The Critical Path Institute (C-Path), together with CHDI Foun
Critical Path Institute Receives Regulatory Support for Liver Injury Biomarker Tucson, AZ — January 22, 2018 — Critical Path Institute (C-Path) announced today that the European Medicines Agency (E
C-Path and CDISC Announce Therapeutic Area User Guide for Duchenne Muscular Dystrophy October 18, 2017 TUCSON, Ariz., and AUSTIN, Texas – October 18, 2017 –Critical Path Institute (C-Path) and The
C-Path, CHDI Foundation, and CDISC Announce Public Review Period for Huntington’s Disease Therapeutic Area User Guide September 11, 2017 TUCSON, AZ, NEW YORK, NY, and AUSTIN, TX – September 11, 2017 – Critical Path Institute (C-Pa
C-Path and CDISC Announce Public Review Period for Duchenne Therapeutic Area Standard June 13, 2017 TUCSON, Ariz., and AUSTIN, Texas – June 13, 2017 – The Clinical Data Interchange Standards Consort
Two Arizona leaders in scientific collaboration partner to advance global TB research May 1, 2017 Two Arizona leaders in scientific collaboration partner to advance global TB research TUCSON and FLAGSTA
Critical Path Institute and TGen Forge Partnership to Advance TB Research May 1, 2017 Critical Path Institute and TGen Forge Partnership to Advance TB Research TUCSON and FLAGSTAFF, May 1,
